Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 48, Issue 1, Pages 271-280Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST20190694
Keywords
-
Categories
Funding
- Astex Pharmaceuticals
Ask authors/readers for more resources
Fragment-based drug discovery (FBDD) has become a mainstream technology for the identification of chemical hit matter in drug discovery programs. To date, the food and drug administration has approved four drugs, and over forty compounds are in clinical studies that can trace their origins to a fragment-based screen. The challenges associated with implementing an FBDD approach are many and diverse, ranging from the library design to developing methods for identifying weak affinity compounds. In this article, we give an overview of current progress in fragment library design, fragment to lead optimisation and on the advancement in techniques used for screening. Finally, we will comment on the future opportunities and challenges in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available